Конференция, посвященная Т-клеточной лимфоме (T-Cell Lymphoma Forum) пройдет в Лихаине(Гавайски Острова, США) с 28 по 30 января 2010.

Официальный сайт Конференции.

Официальная программа:

THURSDAY, JANUARY 28 4:00-4:05 Welcome and Introduction: Francine M. Foss (New Haven), Kensei Tobinai (Tokyo) 4:05-4:25 Introduction—PTCL: The global picture: Julie M. Vose (Omaha) SESSION 1 Classification, epidemiology, and prognosis Moderators: Stefano A. Pileri (Bologna), John (Wing) C Chan (Omaha) 4:25-4:40 Classification of peripheral T-cell lymphomas: Stefano A. Pileri (Bologna) 4:40-4:55 Pathobiology of malignant adult T-cell leukemia/lymphoma (ATLL): Thomas A. Waldmann (Bethesda) 4:55-5:10 Lymphoma phenotypes in Asia: Kohichi Ohshima (Kurume) 5:10-5:25 Lymphoma phenotypes in the West: TBD (Vancouver) 5:25-5:45 Discussion 5:45-7:00 Welcome dinner 7:00-7:15 Molecular biology in Asia: Masao Seto (Nagoya) 7:15-7:30 Genomic profiling in T-cell lymphomas: Pier Paolo Piccaluga (Bologna) 7:30-7:45 Signal transduction in T-cell lymphomas: Mariusz Wasik (Philadelphia) 7:45-8:00 Predicting prognosis: Prognostic index for T-cell lymphoma (PIT), international prognostic index (IPI), and Korean model for extranodal NK/T-cell lymphoma, nasal type: Stefano A. Pileri (Bologna) 8:00-8:10 Poster presentation 8:10-8:30 Discussion 8:30-8:35 Wrap-up: Kensei Tobinai (Tokyo), Francine M. Foss (New Haven)

FRIDAY, JANUARY 29 7:00-8:00 Breakfast 8:00-8:05 House business: Kensei Tobinai (Tokyo) SESSION 2 NK-cell lymphomas Moderators: Kohichi Ohshima (Kurume), Shigeo Nakamura (Nagoya) 8:05-8:20 Extranodal NK/T-cell lymphoma, nasal type: Yok-Lam Kwong (Hong Kong) 8:20-8:35 Pediatric EBV+ T-cell lymphoproliferative disease: Hiroshi Kimura (Nagoya) 8:35-8:50 Chronic and aggressive NK-cell proliferations: John (Wing) C Chan (Omaha) 8:50-9:05 SMILE protocol for advanced or relapsed/refractory NK-cell lymphomas: Ritsuro Suzuki (Nagoya) 9:05-9:15 Poster presentation 9:15-9:35 Discussion 9:35-9:50 Break

SESSION 3 Virus-associated lymphomas Moderators: Kensei Tobinai (Tokyo), Thomas A. Waldmann (Bethesda) 9:50-10:05 Molecular mechanisms of oncogenesis by human T-cell leukemia virus type 1: Masao Matsuoka (Kyoto) 10:05-10:20 Receptor-targeted therapies for T-cell malignancies: Thomas A. Waldmann (Bethesda) 10:20-10:35 EBV-associated T-cell lymphoma: Shigeo Nakamura (Nagoya) 10:35-10:45 Poster presentation 10:45-11:00 Discussion 11:00-1:30 Mid-day break SESSION 4 Cutaneous lymphomas Moderators: Madeleine Duvic (Houston), Sean Whittaker (London) 1:30-1:45 Molecular data: Sean Whittaker (London) 1:45-2:00 CD30+ neoplasms of the skin: Madeleine Duvic (Houston) 2:00-2:15 Mycosis fungoides: Steven M. Horwitz (New York) 2:15-2:30 Sezary syndrome: Cornelius P. Tensen (Leiden) 2:30-2:45 Diagnosing and distinguishing benign vs malignant disease: Youn Kim (Stanford) 2:45-3:30 ISCL update: Francine M. Foss (New Haven) 3:30-3:40 Poster presentation 3:40-4:00 Discussion 4:00-4:15 Break SESSION 5 Treatment approaches to T-cell lymphomas Moderators: Steven T. Rosen (Chicago), Owen A. O’Connor (New York) 4:15-4:30 NCCN guidelines: Ranjana Advani (Stanford) 4:30-4:45 Treatment approaches for PTCL: Pier Luigi Zinzani (Bologna) 4:45-5:00 Treatment approaches for localized nasal NK-cell lymphomas: Motoko Yamaguchi (Tsu) 5:00-5:15 Treatment approaches for HTLV-1-associated T-cell lymphomas: Kunihiro Tsukasaki (Nagasaki) 5:15-5:25 Poster presentation 5:25-5:45 Discussion: Developing better treatment algorithms

SATURDAY, JANUARY 30 7:00-8:00 Breakfast 8:00-8:05 House business: Francine M. Foss (New Haven) SESSION 6 Therapy in T-cell lymphomas Moderators: Francine M. Foss (New Haven), Pier Luigi Zinzani (Bologna) 8:05-8:20 New chemotherapies: Owen A. O’Connor (New York) 8:20-8:35 Monoclonal antibodies—I: Francesco d’Amore (Aarhus) 8:35-8:50 Monoclonal antibodies—II: Kensei Tobinai (Tokyo) 8:50-9:05 Role of nucleoside analogues: Claire E. Dearden (London) 9:05-9:20 Epigenetic modifications in PTCL: Francine M. Foss (New Haven) 9:20-9:35 Immunomodulatory agents and immunotoxins: Steven T. Rosen (Chicago) 9:35-9:50 Apoptotic inhibitors: Christiane Querfeld (Chicago) 9:50-10:05 Signal transduction and kinase inhibitors: Julie M. Vose (Omaha) 10:05-10:20 Proteasome inhibitors: Won Seog Kim (Seoul) 10:20-10:30 Poster presentation 10:30-10:50 Discussion 10:50-11:00 Break SESSION 7 Transplantation Moderators: Julie M. Vose (Omaha), Ryuji Tanosaki (Tokyo) 11:00-11:15 Allogeneic transplant—IBMTR data: Sonali Smith (Chicago) 11:15-11:30 Autologous transplant: Andrei Shustov (Seattle) 11:30-11:45 Transplantation in HTLV-1-associated T-cell Lymphomas: Ryuji Tanosaki (Tokyo) 11:45-11:55 Poster presentation 11:55-12:15 Discussion SESSION 8 Design of multicenter trials in PTCL: Next steps and discussion Moderators: Francine M. Foss (New Haven), Kensei Tobinai (Tokyo) 12:15-12:30 PTCL European trials: Peter Reimer (Würzburg) 12:30-12:45 CTCL European trials: Sean Whittaker (London) 12:45-1:00 Asian cooperative group trials in T-cell lymphoma: Kensei Tobinai (Tokyo) 1:00-1:20 Discussion 1:20-1:25 Summary and adjournment 1:25 Lunch and departures